• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: Impact of the Epidermal Growth Factor Receptor Exon 20 Q787Q Mutation on the Clinical Course of Non-Small-Cell Lung Cancer.

作者信息

Sonoda Dai, Kondo Yasuto, Maruyama Raito, Mitsuhashi Shunsuke, Tamagawa Satoru, Naito Masahito, Mikubo Masashi, Shiomi Kazu, Satoh Yukitoshi

机构信息

Department of Thoracic Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.

Department of Thoracic Surgery, Kitasato University Medical Center, Kitamoto, Saitama, Japan.

出版信息

Ann Surg Oncol. 2025 Sep 10. doi: 10.1245/s10434-025-18270-0.

DOI:10.1245/s10434-025-18270-0
PMID:40931309
Abstract
摘要

相似文献

1
ASO Author Reflections: Impact of the Epidermal Growth Factor Receptor Exon 20 Q787Q Mutation on the Clinical Course of Non-Small-Cell Lung Cancer.ASO作者反思：表皮生长因子受体第20外显子Q787Q突变对非小细胞肺癌临床病程的影响
Ann Surg Oncol. 2025 Sep 10. doi: 10.1245/s10434-025-18270-0.
2
Characteristics of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Q787Q Mutation.非小细胞肺癌及表皮生长因子受体外显子20 Q787Q突变患者的特征
Ann Surg Oncol. 2025 Aug 24. doi: 10.1245/s10434-025-18143-6.
3
Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy.表皮生长因子受体酪氨酸激酶抑制剂初治的非小细胞肺癌中表皮生长因子受体的罕见突变及对厄洛替尼治疗的反应
J Cancer Res Ther. 2020 Jan-Mar;16(1):132-138. doi: 10.4103/jcrt.JCRT_757_19.
4
Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.酪氨酸激酶抑制剂治疗后携带表皮生长因子受体第19外显子或第21外显子突变的非小细胞肺癌患者临床结局的比较：一项荟萃分析
Eur J Clin Pharmacol. 2016 Jan;72(1):1-11. doi: 10.1007/s00228-015-1966-0.
5
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.辅助性表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）用于治疗已切除的Ⅰ至Ⅲ期非小细胞肺癌且伴有EGFR突变的患者。
Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2.
6
REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with exon 20 insertion-mutated NSCLC.REZILIENT3：一线使用齐帕替尼联合化疗治疗20号外显子插入突变非小细胞肺癌患者的随机III期研究
Future Oncol. 2025 Feb;21(5):549-556. doi: 10.1080/14796694.2025.2457294. Epub 2025 Feb 16.
7
EGFR Q787Q Polymorphism Is a Germline Variant and a Prognostic Factor for Lung Cancer Treated With TKIs.表皮生长因子受体（EGFR）Q787Q多态性是一种种系变异，也是接受酪氨酸激酶抑制剂（TKIs）治疗的肺癌的一个预后因素。
Front Oncol. 2022 Mar 21;12:816801. doi: 10.3389/fonc.2022.816801. eCollection 2022.
8
Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer.吸烟对韩国非小细胞肺癌患者表皮生长因子受体基因突变频率和谱的影响。
J Cancer Res Clin Oncol. 2010 Dec;136(12):1937-44. doi: 10.1007/s00432-010-0853-4. Epub 2010 Mar 17.
9
Evaluation of epidermal growth factor receptor mutations and thyroid transcription factor-1 status in Turkish non-small cell lung carcinoma patients: A study of 600 cases from a single center.土耳其非小细胞肺癌患者表皮生长因子受体突变及甲状腺转录因子-1状态的评估：来自单一中心的600例病例研究
Turk Gogus Kalp Damar Cerrahisi Derg. 2020 Jan 23;28(1):143-150. doi: 10.5606/tgkdc.dergisi.2020.18196. eCollection 2020 Jan.
10
Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.表皮生长因子受体（EGFR）同义变体p.Q787Q对肺腺癌患者既无预后价值也无预测价值。
Genes Chromosomes Cancer. 2017 Mar;56(3):214-220. doi: 10.1002/gcc.22427. Epub 2016 Nov 30.

本文引用的文献

1
Characteristics of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Q787Q Mutation.非小细胞肺癌及表皮生长因子受体外显子20 Q787Q突变患者的特征
Ann Surg Oncol. 2025 Aug 24. doi: 10.1245/s10434-025-18143-6.
2
Optimizing the clinical management of -mutant advanced non-small cell lung cancer: a literature review.优化-突变型晚期非小细胞肺癌的临床管理：一项文献综述。
Transl Lung Cancer Res. 2022 May;11(5):935-949. doi: 10.21037/tlcr-22-1.
3
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
阿法替尼治疗具有罕见表皮生长因子受体（EGFR）突变的非小细胞肺癌：一个包含693例病例的数据库。
J Thorac Oncol. 2020 May;15(5):803-815. doi: 10.1016/j.jtho.2019.12.126. Epub 2020 Jan 10.
4
A pan-cancer analysis of synonymous mutations.泛癌症中同义突变的分析。
Nat Commun. 2019 Jun 12;10(1):2569. doi: 10.1038/s41467-019-10489-2.
5
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.非小细胞肺癌患者罕见表皮生长因子受体（EGFR）突变的综合综述。
Lung Cancer. 2017 Dec;114:96-102. doi: 10.1016/j.lungcan.2017.11.005. Epub 2017 Nov 7.
6
EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung.中国肺腺鳞癌患者的 EGFR 和 KRAS 突变。
Lung Cancer. 2011 Dec;74(3):396-400. doi: 10.1016/j.lungcan.2011.04.005. Epub 2011 May 17.